Page 20 - Multiple Sclerosis Ms News Today

Updated European guidelines also include a recommendation for siponimod in progressive MS and more detailed information on drug use in pregnancy.

Different prognostic variables come together into a single predictive score.

The new anti-CD20 monoclonal antibody showed significant improvement in the multiple sclerosis functional composite (MSFC) score, a measure of disability, compared with teriflunomide.

Multiple sclerosis is a complex disease with many treatment options. Experts discuss how to improve communication with patients and facilitate joint decision-making for better disease management.

Rituximab reduced relapses and MRI activity more effectively than dimethyl fumarate, natalizumab, and injectable therapies in a recent study. Disability did not differ between treatments, however.

Findings presented at ECTRIMS 2021 suggest the OTC supplement improves multiple sleep measures

The statement concludes that COVID-19 vaccines are safe for patients with multiple sclerosis and that most MS patients gain the same protection as the general population. But there are exceptions.

New data on COVID vaccination in MS patients has shown a reduced humoral response in patients treated with certain medications -- including ocrelizumab, rituximab, and fingolimod -- but not others.

Patients who developed secondary progressive MS at 20 years had more cortical lesions at baseline than patients with clinically isolated syndrome, relapsing-remitting MS, or primary progressive MS.

A statement by the American Academy of Neurology, American Neurological Association, and Child Neurology Society details ethical concerns about high drug prices -- and what neurologists can do.